Cyclopharm

Cyclopharm is an Australian ASX listed medical device company primarily involved in the field of nuclear medicine.
Technegas, Cyclopharm’s foundation product is a lung ventilation imaging agent, is a structured ultra-fine dispersion of radioactive labeled carbon. Technegas is produced by drying Technetium-99m, (the most commonly used isotope in nuclear medicine imaging), in a carbon crucible then heating the isotope for a few seconds at around 2,700oC in a Technegas Generator. The resultant gas-like substance is inhaled by the patient (referred to as lung ventilation) via our consumable product known as a Patient Administration Set (PAS).
The inhaled Technegas particles enables multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for superior functional ventilation imaging. Technegas is best known for its use in diagnosing Pulmonary Embolism (PE); however, Technegas is now being investigated for additional indications to include the diagnosis and management of COPD, Asthma, CTEPH and the effectiveness of lung reduction interventions
Ultralute, a new product developed by Cyclopharm will be released to the market later in 2016. This first in class, proprietary technology is designed to improve the efficiency, productivity and health care economics in the production of radiopharmaceuticals.

Company’s Keywords:

nuclear medicine, diagnostic imaging, medical devices, respiratory medicine